This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
1 Apr 2015

Repurposed Experimental Cancer Drug Restores Brain Function in Mouse Models of Alzheimer’s Disease

Scientists have found that a compound originally developed as a cancer therapy potentially could be used to treat Alzheimer’s disease. The team demonstrated that the drug, saracatinib, restores memory loss and reverses brain problems in mouse models of Alzheimer’s, and now the researchers are testing saracatinib’s effectiveness in humans. The study was funded by the National Institutes of Health as part of an innovative crowdsourcing initiative to repurpose experimental drugs.

 

Researchers from the Yale University School of Medicine, New Haven, Connecticut, conducted the animal study, published for early view on 21 March in the Annals of Neurology External Web Site Policy, with support from the National Center for Advancing Translational Sciences (NCATS) through its Discovering New Therapeutic Uses for Existing Molecules (New Therapeutic Uses) program. Launched in May 2012, this program matches scientists with a selection of pharmaceutical industry assets that have undergone significant research and development by industry, including safety testing in humans, to test potential ideas for new therapeutic uses.

 

Through NCATS’ New Therapeutic Uses program, Yale neurobiology researcher, neurologist and senior author of the study Stephen Strittmatter and his colleagues obtained saracatinib (AZD0530), which the biopharmaceutical company AstraZeneca previously developed to treat cancer. Strittmatter and his team knew from previous studies that a protein called Fyn kinase plays a central role in how amyloid beta clusters damage brain cells. Saracatinib targets the same Fyn protein and already had cleared several key steps in the development process, giving Strittmatter’s team a critical head start on the research.

 

“The investigational drug already had been developed, optimized and studied in animals as well as tested for safety in humans, so our ability to obtain this asset through NCATS and AstraZeneca gave us an incredible shortcut in the drug development process,” Strittmatter explained.

 

Typically, drug development can take at least a decade from the discovery of a therapeutic target to an experimental compound’s entry into a Phase IIa human clinical trial to test effectiveness. In the case of saracatinib, the research team completed required preclinical and clinical safety studies and began a Phase IIa trial within about 18 months.

 

“This work demonstrates what can happen when NIH, the biopharmaceutical industry and academia innovate and collaborate to share resources and knowledge,” said NCATS Director Christopher P. Austin. “The speed with which this compound moved to human trials validates our New Therapeutic Uses program model and serves NCATS’ mission to deliver more treatments to more patients more quickly.”

 

“No one individual or group has complete knowledge of disease pathways and treatment targets,” said Craig D. Wegner, Ph.D., head, Boston Emerging Innovations Unit, Scientific Partnering & Alliances within AstraZeneca’s Innovative Medicines and Early Development Biotech Unit. “This program enabled us to pair AstraZeneca’s data on this compound with the Strittmatter group’s specialized Alzheimer’s disease knowledge to uncover a potential new therapeutic use for saracatinib. It’s a great example of how scientists from industry and academia can synergistically work together to push the boundaries of medical science.”

Related News